MDLN vs SLN: fair value comparison
Medline Inc. and Silence Therapeutics plc · Updated 2026-10-19
MDLN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. SLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MDLN currently ranks higher by quality score.
| MDLN | SLN | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $35.96 | $8.68 |
| 12-month range | $31.64–$49.99 | $4.30–$15.43 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #211 of 301 Healthcare | #213 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: MDLN fair value analysis · SLN fair value analysis